These 5 Reasons Support a Purchase of Vertex Pharmaceuticals

I find Vertex Pharmaceuticals (VRTX) interesting for new long maneuvers for five specific reasons. The SPDR S&P Biotech ETF (XBI) has improved by about 79% over the past twelve months and is now approaching the new 52-week high marked at 165.71 USD in July. The core business in cystic fibrosis (CF) grew by 11% in the second quarter, with ALYFTREK, as a triple combination and new generation of CF therapy, rapidly gaining market shares with a growth of 266%. The gene scissors CASGEVY (+151%) and JOURNAVAX (+317%) as non-opioid painkillers...